MRI perfusion in determining pseudoprogression in patients with glioblastoma
- 11 April 2012
- journal article
- research article
- Published by Elsevier BV in Clinical Imaging
- Vol. 37 (1), 41-49
- https://doi.org/10.1016/j.clinimag.2012.02.016
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic AssessmentClinical Cancer Research, 2011
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma MultiformeJournal of Clinical Oncology, 2011
- Advanced MRI and PET imaging for assessment of treatment response in patients with gliomasThe Lancet Neurology, 2010
- Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade GliomaJournal of Clinical Oncology, 2010
- Potential for Differentiation of Pseudoprogression From True Tumor Progression With Dynamic Susceptibility-Weighted Contrast-Enhanced Magnetic Resonance Imaging Using Ferumoxytol vs. Gadoteridol: A Pilot StudyInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR ImagingRadiology, 2009
- Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed GlioblastomaJournal of Clinical Oncology, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Advanced imaging techniques in brain tumorsCancer Imaging, 2009